20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Alumis Inc (ALMS) operates in the BIOTECHNOLOGY industry and is headquartered in South San Francisco, United States with about 237 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, ALMS reported $24M in revenue and ($243M) in net income.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
Interactive charts & full statements → Open the ALMS valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $8M | $24M | $0M | $0M | $0M |
| Gross Profit | $7M | $21M | ($3M) | ($1M) | $0M |
| Gross Margin % | 87.5% | 85.5% | — | — | — |
| Operating Income (EBIT) | ($458M) | ($427M) | ($301M) | ($158M) | ($114M) |
| Operating Margin % | -5725.0% | -1776.3% | — | — | — |
| Net Income | ($439M) | ($243M) | ($294M) | ($155M) | ($112M) |
| Net Margin % | -5487.5% | -1011.8% | — | — | — |
| EBITDA | ($443M) | ($248M) | ($291M) | ($154M) | ($112M) |
| Earnings Per Share (EPS) | $-3.80 | $-0.29 | $-10.38 | $-2.99 | $-14.93 |
| Shares Outstanding (M) | 128M | — | 28M | — | 7M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $2M | $2M | $2M | $2M | $3M | $17M | $3M | $0M |
| Gross Profit | $2M | $1M | $2M | $2M | $3M | $17M | ($1M) | ($1M) |
| Gross Margin % | 100.0% | 50.0% | 100.0% | 100.0% | 100.0% | 100.0% | -27.0% | — |
| Operating Income (EBIT) | ($149M) | ($98M) | ($96M) | ($115M) | ($141M) | ($102M) | ($99M) | ($98M) |
| Operating Margin % | -8956.4% | -5652.4% | -4999.7% | -5580.4% | -5271.5% | -583.9% | -3248.4% | — |
| Net Income | ($142M) | ($93M) | ($93M) | ($111M) | $59M | ($99M) | ($95M) | ($93M) |
| Net Margin % | -8557.2% | -5344.8% | -4817.6% | -5360.7% | 2225.1% | -569.1% | -3121.2% | — |
| EBITDA | ($149M) | ($92M) | ($92M) | ($110M) | ($120M) | ($98M) | ($94M) | ($92M) |
| Earnings Per Share (EPS) | $-1.11 | $-0.74 | $-0.89 | $-1.06 | $0.77 | $-1.82 | $-1.76 | $-1.73 |
| Shares Outstanding (M) | 128M | 125M | 105M | 104M | 77M | 54M | 54M | 54M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($352M) | ($370M) | ($255M) | ($130M) | ($108M) |
| Capital Expenditures (CapEx) | $0M | $1M | $2M | $4M | $2M |
| Free Cash Flow (FCF) | ($352M) | ($370M) | ($257M) | ($134M) | ($110M) |
| FCF Margin % | -4400.0% | -1539.2% | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($82M) | ($87M) | ($72M) | ($111M) | ($106M) | ($80M) | ($75M) | ($84M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $1M | $0M | $0M | $1M |
| Free Cash Flow (FCF) | ($82M) | ($87M) | ($72M) | ($111M) | ($107M) | ($80M) | ($75M) | ($85M) |
| FCF Margin % | -4918.0% | -5011.3% | -3727.7% | -5368.3% | -4012.3% | -462.3% | -2474.6% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets | $561M | $412M | $341M | $90M | $108M |
| Cash & Cash Equivalents | $64M | $90M | $170M | $46M | $26M |
| Total Liabilities | $108M | $111M | $81M | $429M | $303M |
| Total Debt (Short + Long-Term) | $5M | $5M | $2M | $2M | $1M |
| Total Shareholders' Equity | $452M | $301M | $260M | ($339M) | ($195M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ALMS viewer.
About TickerBase · Data methodology & sources · Privacy · Terms